Mayer, Marie-Christina
Berg, Johannes Lorenz
Perfler, Bianca
Hatzl, Stefan
Herzog, Sereina Annik
Bachmaier, Gerhard
Berghold, Andrea
Reinisch, Andreas
Wölfler, Albert
Sill, Heinz
Zebisch, Armin http://orcid.org/0000-0002-4861-7021
Funding for this research was provided by:
Austrian Science Fund (P 31430-458 B26, P32783)
Österreichische Gesellschaft für Innere Medizin (Joseph-Skoda Award, Joseph-Skoda Award)
Leukämiehilfe Steiermark
Österreichische Gesellschaft für Hämatologie und Onkologie (Clinical Research Grant)
MEFOgraz
Article History
Received: 21 June 2021
Accepted: 6 July 2021
First Online: 22 July 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of the Medical University of Graz (EK 30–464 ex 17/18). Informed consent was obtained from all patients for being included in the study.
: Informed consent was obtained from all individual participants included in the study.
: A.R.: research support from Celgene/BMS; A.W.: research support from Celgene/BMS. Honoraria for lectures from Celgene/BMS, Novartis, Ariad, Pfizer and Astellas. H.S.: Consultancy for Celgene/BMS and AbbVie; A.Z.: Consultancy for Celgene/BMS. Participation in Advisory boards for AbbVie and Novartis. Honoraria for lectures from Novartis; all other authors declare no conflict of interest.